Zuellig Pharma has expanded its partnership with Lundbeck to enhance the commercialization of neuro-psychiatric health solutions across Asia. This collaboration will leverage Zuellig Pharma's extensive distribution network and market expertise to bring innovative treatments for neurological and psychiatric conditions to a wider patient population. The expanded partnership aims to improve access to specialized healthcare solutions in the region.
This expanded partnership is crucial for improving access to specialized neuro-psychiatric treatments across Asia, a region with significant unmet needs in mental health. By combining Lundbeck's innovative therapies with Zuellig Pharma's robust commercialization capabilities, more patients will benefit from advanced healthcare solutions, addressing a critical public health challenge and fostering better patient outcomes.
Zuellig Pharma and Lundbeck expanded their partnership.
The collaboration focuses on commercializing neuro-psychiatric health solutions.
This aims to improve access to treatments across Asia.
The expanded partnership directly addresses the growing need for neuro-psychiatric health solutions in APAC, leveraging Zuellig Pharma's regional reach to improve access to specialized treatments for a significant patient population.
This aims to improve access to treatments across Asia.
It leverages Zuellig Pharma's distribution and market expertise.
Sign in to save notes on signals.
Sign In